Ann: US FDA Type C Meeting for ATL1102 in DMD, page-56

Its not just your opinion V. Its a perfectly correct and accurate intepretation of the ann. "Reassured" is extremely positive and we are most definitely heading straight into a 2b/3 trial. This is the best news anyone could have hoped for. Theyve said everything they can without 100% confirmation as that can only come from the minutes, in writting, officially.

The questions are around dosage, funding, trial length, patient numbers, start date... these will align with the EU trial most likely as per Uboys predictions. We may even be awarded Fast Track Designation at this stage, perhaps Mac9 may have an opinion here.

ATL1102 will be looking at market approval by end of next year / early 2023, generating millions from a broad client base, whilst following through with other indications to keep the news flowing.

The Wilsons and Morgans upper end price targets are looking to be the most likely outcomes; the best case scenario is playing out, and other brokers with lower targets will need to adjust and update very soon based on this announcement's big brother - confirmation of all that is obvious written clearly in your post above. Thanks for that.